During the past decade, Azienda Ospedaliero Universitaria Pisana conducted 367 clinical trials. In the 10-year time frame, 367 clinical trials started and 129 clinical trials were completed, i.e. on average, 35.1% percent of trials that started reached the finish line to date. In the past 5 years, 181 clinical trials started and 87 clinical trials were completed. i.e. 48.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliero Universitaria Pisana" #1 sponsor was "Hoffmann-La Roche" with 70 trials, followed by "Azienda Ospedaliero, Universitaria Pisana" with 26 trials sponsored, "Celgene" with 20 trials sponsored, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 15 trials sponsored and "Janssen Research & Development, LLC" with 15 trials sponsored. Other sponsors include 361 different institutions and companies that sponsored additional 182 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliero Universitaria Pisana" #1 collaborator was "Eli Lilly and Company" with 9 trials as a collaborator, "Azienda Ospedaliero, Universitaria Pisana" with 8 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 6 trials as a collaborator, "Incyte Corporation" with 5 trials as a collaborator and "Hoffmann-La Roche" with 4 trials as a collaborator. Other collaborators include 177 different institutions and companies that were collaborators in the rest 163 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliero Universitaria Pisana" are "Breast Cancer" (14 trials), "Metastatic Colorectal Cancer" (13 trials), "Ulcerative Colitis" (11 trials), "Gastric Cancer" (9 trials) and "Hepatitis B, Chronic" (9 trials). Many other conditions were trialed in "Azienda Ospedaliero Universitaria Pisana" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliero Universitaria Pisana" are "Drug" (374 trials), "Other" (51 trials), "Device" (39 trials), "Procedure" (35 trials) and "Biological" (29 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (86 trials), "Atezolizumab" (24 trials), "Carboplatin" (15 trials), "Cisplatin" (15 trials) and "Gemcitabine" (15 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliero Universitaria Pisana" are 478 trials for "All" genders, 27 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are 189 active trials in "Azienda Ospedaliero Universitaria Pisana". 3 are not yet recruiting, 100 are recruiting, 83 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 236 completed trials in Azienda Ospedaliero Universitaria Pisana, undefined suspended trials, and 35 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliero Universitaria Pisana, 16 "Phase 1" clinical trials were conducted, 122 "Phase 2" clinical trials and 225 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 26 trials, and there were also 45 trials that are defined as “Not Applicable".